Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 3.7%

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRXGet Free Report) shares fell 3.7% on Monday . The stock traded as low as $2.29 and last traded at $2.31. 325,324 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 4,804,619 shares. The stock had previously closed at $2.40.

Lexicon Pharmaceuticals Price Performance

The firm’s 50 day moving average price is $2.38 and its two-hundred day moving average price is $1.63. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.60 and a quick ratio of 5.58.

Lexicon Pharmaceuticals (NASDAQ:LXRXGet Free Report) last issued its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. On average, equities research analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Stifel Financial Corp grew its stake in Lexicon Pharmaceuticals by 3.1% in the 1st quarter. Stifel Financial Corp now owns 128,311 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,827 shares in the last quarter. Jane Street Group LLC grew its stake in Lexicon Pharmaceuticals by 11.8% in the 1st quarter. Jane Street Group LLC now owns 43,523 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 4,592 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Lexicon Pharmaceuticals by 5.6% in the 4th quarter. Alliancebernstein L.P. now owns 89,811 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 4,800 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Lexicon Pharmaceuticals by 22.0% in the 4th quarter. Victory Capital Management Inc. now owns 32,187 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 5,813 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Lexicon Pharmaceuticals by 5.0% in the 1st quarter. Rhumbline Advisers now owns 125,066 shares of the biopharmaceutical company’s stock worth $304,000 after acquiring an additional 5,949 shares during the last quarter. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

(Get Free Report)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

Read More

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.